BiopestPeptidV1, Main, Exploration, bibRecord, 000051

Peptides: Prospects for Use in the Treatment of COVID-19.

Identifieur interne : 000051 ( Main/Exploration ); précédent : 000050; suivant : 000052

Peptides: Prospects for Use in the Treatment of COVID-19.

Auteurs : Vladimir Khavinson [Russie] ; Natalia Linkova [Russie] ; Anastasiia Dyatlova [Russie] ; Boris Kuznik [Russie] ; Roman Umnov [Russie]

Source :

Molecules (Basel, Switzerland) [ 1420-3049 ] ; 2020.

RBID : pubmed:32987757

Descripteurs français

KwdFr :
- Agents de l'appareil respiratoire (synthèse chimique), Agents de l'appareil respiratoire (usage thérapeutique), Anti-inflammatoires (synthèse chimique), Anti-inflammatoires (usage thérapeutique), Antiviraux (synthèse chimique), Antiviraux (usage thérapeutique), Betacoronavirus (croissance et développement), Betacoronavirus (effets des médicaments et des substances chimiques), Coagulation intravasculaire disséminée (complications), Coagulation intravasculaire disséminée (diagnostic), Coagulation intravasculaire disséminée (traitement médicamenteux), Coagulation intravasculaire disséminée (virologie), Facteurs immunologiques (synthèse chimique), Facteurs immunologiques (usage thérapeutique), Humains (MeSH), Infections à coronavirus (complications), Infections à coronavirus (diagnostic), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Insuffisance respiratoire (complications), Insuffisance respiratoire (diagnostic), Insuffisance respiratoire (prévention et contrôle), Insuffisance respiratoire (virologie), Interactions hôte-pathogène (effets des médicaments et des substances chimiques), Maladie aigüe (MeSH), Pandémies (MeSH), Peptides (synthèse chimique), Peptides (usage thérapeutique), Pneumopathie virale (complications), Pneumopathie virale (diagnostic), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (virologie), Poumon (anatomopathologie), Poumon (effets des médicaments et des substances chimiques), Poumon (vascularisation), Poumon (virologie), Relation structure-activité (MeSH).
MESH :
- anatomopathologie : Poumon.
- croissance et développement : Betacoronavirus.
- diagnostic : Coagulation intravasculaire disséminée, Infections à coronavirus, Insuffisance respiratoire, Pneumopathie virale.
- effets des médicaments et des substances chimiques : Betacoronavirus, Interactions hôte-pathogène, Poumon.
- prévention et contrôle : Insuffisance respiratoire.
- synthèse chimique : Agents de l'appareil respiratoire, Anti-inflammatoires, Antiviraux, Coagulation intravasculaire disséminée, Facteurs immunologiques, Infections à coronavirus, Insuffisance respiratoire, Peptides, Pneumopathie virale.
- traitement médicamenteux : Coagulation intravasculaire disséminée, Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Agents de l'appareil respiratoire, Anti-inflammatoires, Antiviraux, Facteurs immunologiques, Peptides.
- vascularisation : Poumon.
- virologie : Coagulation intravasculaire disséminée, Infections à coronavirus, Insuffisance respiratoire, Pneumopathie virale, Poumon.
- Humains, Maladie aigüe, Pandémies, Relation structure-activité.

English descriptors

KwdEn :
- Acute Disease (MeSH), Anti-Inflammatory Agents (chemical synthesis), Anti-Inflammatory Agents (therapeutic use), Antiviral Agents (chemical synthesis), Antiviral Agents (therapeutic use), Betacoronavirus (drug effects), Betacoronavirus (growth & development), Coronavirus Infections (complications), Coronavirus Infections (diagnosis), Coronavirus Infections (drug therapy), Coronavirus Infections (virology), Cytokine Release Syndrome (complications), Cytokine Release Syndrome (diagnosis), Cytokine Release Syndrome (drug therapy), Cytokine Release Syndrome (virology), Disseminated Intravascular Coagulation (complications), Disseminated Intravascular Coagulation (diagnosis), Disseminated Intravascular Coagulation (drug therapy), Disseminated Intravascular Coagulation (virology), Host-Pathogen Interactions (drug effects), Humans (MeSH), Immunologic Factors (chemical synthesis), Immunologic Factors (therapeutic use), Lung (blood supply), Lung (drug effects), Lung (pathology), Lung (virology), Pandemics (MeSH), Peptides (chemical synthesis), Peptides (therapeutic use), Pneumonia, Viral (complications), Pneumonia, Viral (diagnosis), Pneumonia, Viral (drug therapy), Pneumonia, Viral (virology), Respiratory Insufficiency (complications), Respiratory Insufficiency (diagnosis), Respiratory Insufficiency (prevention & control), Respiratory Insufficiency (virology), Respiratory System Agents (chemical synthesis), Respiratory System Agents (therapeutic use), Structure-Activity Relationship (MeSH).
MESH :
- chemical , chemical synthesis : Anti-Inflammatory Agents, Antiviral Agents, Immunologic Factors, Peptides, Respiratory System Agents.
- chemical , therapeutic use : Anti-Inflammatory Agents, Antiviral Agents, Immunologic Factors, Peptides, Respiratory System Agents.
- blood supply : Lung.
- complications : Coronavirus Infections, Cytokine Release Syndrome, Disseminated Intravascular Coagulation, Pneumonia, Viral, Respiratory Insufficiency.
- diagnosis : Coronavirus Infections, Cytokine Release Syndrome, Disseminated Intravascular Coagulation, Pneumonia, Viral, Respiratory Insufficiency.
- drug effects : Betacoronavirus, Host-Pathogen Interactions, Lung.
- drug therapy : Coronavirus Infections, Cytokine Release Syndrome, Disseminated Intravascular Coagulation, Pneumonia, Viral.
- growth & development : Betacoronavirus.
- pathology : Lung.
- prevention & control : Respiratory Insufficiency.
- virology : Coronavirus Infections, Cytokine Release Syndrome, Disseminated Intravascular Coagulation, Lung, Pneumonia, Viral, Respiratory Insufficiency.
- Acute Disease, Humans, Pandemics, Structure-Activity Relationship.

Abstract

There is a vast practice of using antimalarial drugs, RAS inhibitors, serine protease inhibitors, inhibitors of the RNA-dependent RNA polymerase of the virus and immunosuppressants for the treatment of the severe form of COVID-19, which often occurs in patients with chronic diseases and older persons. Currently, the clinical efficacy of these drugs for COVID-19 has not been proven yet. Side effects of antimalarial drugs can worsen the condition of patients and increase the likelihood of death. Peptides, given their physiological mechanism of action, have virtually no side effects. Many of them are geroprotectors and can be used in patients with chronic diseases. Peptides may be able to prevent the development of the pathological process during COVID-19 by inhibiting SARS-CoV-2 virus proteins, thereby having immuno- and bronchoprotective effects on lung cells, and normalizing the state of the hemostasis system. Immunomodulators (RKDVY, EW, KE, AEDG), possessing a physiological mechanism of action at low concentrations, appear to be the most promising group among the peptides. They normalize the cytokines' synthesis and have an anti-inflammatory effect, thereby preventing the development of disseminated intravascular coagulation, acute respiratory distress syndrome and multiple organ failure.

DOI: 10.3390/molecules25194389
PubMed: 32987757
PubMed Central: PMC7583759

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000011
to stream Main, to step Curation: 000011

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Peptides: Prospects for Use in the Treatment of COVID-19.</title>
<author><name sortKey="Khavinson, Vladimir" sort="Khavinson, Vladimir" uniqKey="Khavinson V" first="Vladimir" last="Khavinson">Vladimir Khavinson</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biogerontology, Saint Petersburg Institute of Bioregulation and Gerontology, 197110 Saint Petersburg, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of Biogerontology, Saint Petersburg Institute of Bioregulation and Gerontology, 197110 Saint Petersburg</wicri:regionArea>
<wicri:noRegion>197110 Saint Petersburg</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>The Group of Peptide Regulation of Aging, Pavlov Institute of Physiology of RAS, 199034 St. Petersburg, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>The Group of Peptide Regulation of Aging, Pavlov Institute of Physiology of RAS, 199034 St. Petersburg</wicri:regionArea>
<wicri:noRegion>199034 St. Petersburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Linkova, Natalia" sort="Linkova, Natalia" uniqKey="Linkova N" first="Natalia" last="Linkova">Natalia Linkova</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biogerontology, Saint Petersburg Institute of Bioregulation and Gerontology, 197110 Saint Petersburg, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of Biogerontology, Saint Petersburg Institute of Bioregulation and Gerontology, 197110 Saint Petersburg</wicri:regionArea>
<wicri:noRegion>197110 Saint Petersburg</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Therapy, Geriatry, and Anti-Aging Medicine, Academy of Postgraduate Education under FSBU FSCC of FMBA of Russia, 125310 Moscow, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of Therapy, Geriatry, and Anti-Aging Medicine, Academy of Postgraduate Education under FSBU FSCC of FMBA of Russia, 125310 Moscow</wicri:regionArea>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical and Biological Disciplines, Belgorod State University, 308015 Belgorod, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of Medical and Biological Disciplines, Belgorod State University, 308015 Belgorod</wicri:regionArea>
<wicri:noRegion>308015 Belgorod</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dyatlova, Anastasiia" sort="Dyatlova, Anastasiia" uniqKey="Dyatlova A" first="Anastasiia" last="Dyatlova">Anastasiia Dyatlova</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biogerontology, Saint Petersburg Institute of Bioregulation and Gerontology, 197110 Saint Petersburg, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of Biogerontology, Saint Petersburg Institute of Bioregulation and Gerontology, 197110 Saint Petersburg</wicri:regionArea>
<wicri:noRegion>197110 Saint Petersburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kuznik, Boris" sort="Kuznik, Boris" uniqKey="Kuznik B" first="Boris" last="Kuznik">Boris Kuznik</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of the normal physiology, Chita State Medical Academy, 672000 Chita, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of the normal physiology, Chita State Medical Academy, 672000 Chita</wicri:regionArea>
<wicri:noRegion>672000 Chita</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Umnov, Roman" sort="Umnov, Roman" uniqKey="Umnov R" first="Roman" last="Umnov">Roman Umnov</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biogerontology, Saint Petersburg Institute of Bioregulation and Gerontology, 197110 Saint Petersburg, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of Biogerontology, Saint Petersburg Institute of Bioregulation and Gerontology, 197110 Saint Petersburg</wicri:regionArea>
<wicri:noRegion>197110 Saint Petersburg</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32987757</idno>
<idno type="pmid">32987757</idno>
<idno type="doi">10.3390/molecules25194389</idno>
<idno type="pmc">PMC7583759</idno>
<idno type="wicri:Area/Main/Corpus">000011</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000011</idno>
<idno type="wicri:Area/Main/Curation">000011</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000011</idno>
<idno type="wicri:Area/Main/Exploration">000011</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Peptides: Prospects for Use in the Treatment of COVID-19.</title>
<author><name sortKey="Khavinson, Vladimir" sort="Khavinson, Vladimir" uniqKey="Khavinson V" first="Vladimir" last="Khavinson">Vladimir Khavinson</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biogerontology, Saint Petersburg Institute of Bioregulation and Gerontology, 197110 Saint Petersburg, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of Biogerontology, Saint Petersburg Institute of Bioregulation and Gerontology, 197110 Saint Petersburg</wicri:regionArea>
<wicri:noRegion>197110 Saint Petersburg</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>The Group of Peptide Regulation of Aging, Pavlov Institute of Physiology of RAS, 199034 St. Petersburg, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>The Group of Peptide Regulation of Aging, Pavlov Institute of Physiology of RAS, 199034 St. Petersburg</wicri:regionArea>
<wicri:noRegion>199034 St. Petersburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Linkova, Natalia" sort="Linkova, Natalia" uniqKey="Linkova N" first="Natalia" last="Linkova">Natalia Linkova</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biogerontology, Saint Petersburg Institute of Bioregulation and Gerontology, 197110 Saint Petersburg, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of Biogerontology, Saint Petersburg Institute of Bioregulation and Gerontology, 197110 Saint Petersburg</wicri:regionArea>
<wicri:noRegion>197110 Saint Petersburg</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Therapy, Geriatry, and Anti-Aging Medicine, Academy of Postgraduate Education under FSBU FSCC of FMBA of Russia, 125310 Moscow, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of Therapy, Geriatry, and Anti-Aging Medicine, Academy of Postgraduate Education under FSBU FSCC of FMBA of Russia, 125310 Moscow</wicri:regionArea>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical and Biological Disciplines, Belgorod State University, 308015 Belgorod, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of Medical and Biological Disciplines, Belgorod State University, 308015 Belgorod</wicri:regionArea>
<wicri:noRegion>308015 Belgorod</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dyatlova, Anastasiia" sort="Dyatlova, Anastasiia" uniqKey="Dyatlova A" first="Anastasiia" last="Dyatlova">Anastasiia Dyatlova</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biogerontology, Saint Petersburg Institute of Bioregulation and Gerontology, 197110 Saint Petersburg, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of Biogerontology, Saint Petersburg Institute of Bioregulation and Gerontology, 197110 Saint Petersburg</wicri:regionArea>
<wicri:noRegion>197110 Saint Petersburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kuznik, Boris" sort="Kuznik, Boris" uniqKey="Kuznik B" first="Boris" last="Kuznik">Boris Kuznik</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of the normal physiology, Chita State Medical Academy, 672000 Chita, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of the normal physiology, Chita State Medical Academy, 672000 Chita</wicri:regionArea>
<wicri:noRegion>672000 Chita</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Umnov, Roman" sort="Umnov, Roman" uniqKey="Umnov R" first="Roman" last="Umnov">Roman Umnov</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biogerontology, Saint Petersburg Institute of Bioregulation and Gerontology, 197110 Saint Petersburg, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of Biogerontology, Saint Petersburg Institute of Bioregulation and Gerontology, 197110 Saint Petersburg</wicri:regionArea>
<wicri:noRegion>197110 Saint Petersburg</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Molecules (Basel, Switzerland)</title>
<idno type="eISSN">1420-3049</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute Disease (MeSH)</term>
<term>Anti-Inflammatory Agents (chemical synthesis)</term>
<term>Anti-Inflammatory Agents (therapeutic use)</term>
<term>Antiviral Agents (chemical synthesis)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Betacoronavirus (drug effects)</term>
<term>Betacoronavirus (growth & development)</term>
<term>Coronavirus Infections (complications)</term>
<term>Coronavirus Infections (diagnosis)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (virology)</term>
<term>Cytokine Release Syndrome (complications)</term>
<term>Cytokine Release Syndrome (diagnosis)</term>
<term>Cytokine Release Syndrome (drug therapy)</term>
<term>Cytokine Release Syndrome (virology)</term>
<term>Disseminated Intravascular Coagulation (complications)</term>
<term>Disseminated Intravascular Coagulation (diagnosis)</term>
<term>Disseminated Intravascular Coagulation (drug therapy)</term>
<term>Disseminated Intravascular Coagulation (virology)</term>
<term>Host-Pathogen Interactions (drug effects)</term>
<term>Humans (MeSH)</term>
<term>Immunologic Factors (chemical synthesis)</term>
<term>Immunologic Factors (therapeutic use)</term>
<term>Lung (blood supply)</term>
<term>Lung (drug effects)</term>
<term>Lung (pathology)</term>
<term>Lung (virology)</term>
<term>Pandemics (MeSH)</term>
<term>Peptides (chemical synthesis)</term>
<term>Peptides (therapeutic use)</term>
<term>Pneumonia, Viral (complications)</term>
<term>Pneumonia, Viral (diagnosis)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (virology)</term>
<term>Respiratory Insufficiency (complications)</term>
<term>Respiratory Insufficiency (diagnosis)</term>
<term>Respiratory Insufficiency (prevention & control)</term>
<term>Respiratory Insufficiency (virology)</term>
<term>Respiratory System Agents (chemical synthesis)</term>
<term>Respiratory System Agents (therapeutic use)</term>
<term>Structure-Activity Relationship (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Agents de l'appareil respiratoire (synthèse chimique)</term>
<term>Agents de l'appareil respiratoire (usage thérapeutique)</term>
<term>Anti-inflammatoires (synthèse chimique)</term>
<term>Anti-inflammatoires (usage thérapeutique)</term>
<term>Antiviraux (synthèse chimique)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Betacoronavirus (croissance et développement)</term>
<term>Betacoronavirus (effets des médicaments et des substances chimiques)</term>
<term>Coagulation intravasculaire disséminée (complications)</term>
<term>Coagulation intravasculaire disséminée (diagnostic)</term>
<term>Coagulation intravasculaire disséminée (traitement médicamenteux)</term>
<term>Coagulation intravasculaire disséminée (virologie)</term>
<term>Facteurs immunologiques (synthèse chimique)</term>
<term>Facteurs immunologiques (usage thérapeutique)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (complications)</term>
<term>Infections à coronavirus (diagnostic)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Insuffisance respiratoire (complications)</term>
<term>Insuffisance respiratoire (diagnostic)</term>
<term>Insuffisance respiratoire (prévention et contrôle)</term>
<term>Insuffisance respiratoire (virologie)</term>
<term>Interactions hôte-pathogène (effets des médicaments et des substances chimiques)</term>
<term>Maladie aigüe (MeSH)</term>
<term>Pandémies (MeSH)</term>
<term>Peptides (synthèse chimique)</term>
<term>Peptides (usage thérapeutique)</term>
<term>Pneumopathie virale (complications)</term>
<term>Pneumopathie virale (diagnostic)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Pneumopathie virale (virologie)</term>
<term>Poumon (anatomopathologie)</term>
<term>Poumon (effets des médicaments et des substances chimiques)</term>
<term>Poumon (vascularisation)</term>
<term>Poumon (virologie)</term>
<term>Relation structure-activité (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Anti-Inflammatory Agents</term>
<term>Antiviral Agents</term>
<term>Immunologic Factors</term>
<term>Peptides</term>
<term>Respiratory System Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Inflammatory Agents</term>
<term>Antiviral Agents</term>
<term>Immunologic Factors</term>
<term>Peptides</term>
<term>Respiratory System Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="blood supply" xml:lang="en"><term>Lung</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term>
<term>Cytokine Release Syndrome</term>
<term>Disseminated Intravascular Coagulation</term>
<term>Pneumonia, Viral</term>
<term>Respiratory Insufficiency</term>
</keywords>
<keywords scheme="MESH" qualifier="croissance et développement" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term>
<term>Cytokine Release Syndrome</term>
<term>Disseminated Intravascular Coagulation</term>
<term>Pneumonia, Viral</term>
<term>Respiratory Insufficiency</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Coagulation intravasculaire disséminée</term>
<term>Infections à coronavirus</term>
<term>Insuffisance respiratoire</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term>
<term>Host-Pathogen Interactions</term>
<term>Lung</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Cytokine Release Syndrome</term>
<term>Disseminated Intravascular Coagulation</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term>
<term>Interactions hôte-pathogène</term>
<term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Respiratory Insufficiency</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Insuffisance respiratoire</term>
</keywords>
<keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>Agents de l'appareil respiratoire</term>
<term>Anti-inflammatoires</term>
<term>Antiviraux</term>
<term>Coagulation intravasculaire disséminée</term>
<term>Facteurs immunologiques</term>
<term>Infections à coronavirus</term>
<term>Insuffisance respiratoire</term>
<term>Peptides</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Coagulation intravasculaire disséminée</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents de l'appareil respiratoire</term>
<term>Anti-inflammatoires</term>
<term>Antiviraux</term>
<term>Facteurs immunologiques</term>
<term>Peptides</term>
</keywords>
<keywords scheme="MESH" qualifier="vascularisation" xml:lang="fr"><term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Coagulation intravasculaire disséminée</term>
<term>Infections à coronavirus</term>
<term>Insuffisance respiratoire</term>
<term>Pneumopathie virale</term>
<term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Cytokine Release Syndrome</term>
<term>Disseminated Intravascular Coagulation</term>
<term>Lung</term>
<term>Pneumonia, Viral</term>
<term>Respiratory Insufficiency</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Acute Disease</term>
<term>Humans</term>
<term>Pandemics</term>
<term>Structure-Activity Relationship</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
<term>Maladie aigüe</term>
<term>Pandémies</term>
<term>Relation structure-activité</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">There is a vast practice of using antimalarial drugs, RAS inhibitors, serine protease inhibitors, inhibitors of the RNA-dependent RNA polymerase of the virus and immunosuppressants for the treatment of the severe form of COVID-19, which often occurs in patients with chronic diseases and older persons. Currently, the clinical efficacy of these drugs for COVID-19 has not been proven yet. Side effects of antimalarial drugs can worsen the condition of patients and increase the likelihood of death. Peptides, given their physiological mechanism of action, have virtually no side effects. Many of them are geroprotectors and can be used in patients with chronic diseases. Peptides may be able to prevent the development of the pathological process during COVID-19 by inhibiting SARS-CoV-2 virus proteins, thereby having immuno- and bronchoprotective effects on lung cells, and normalizing the state of the hemostasis system. Immunomodulators (RKDVY, EW, KE, AEDG), possessing a physiological mechanism of action at low concentrations, appear to be the most promising group among the peptides. They normalize the cytokines' synthesis and have an anti-inflammatory effect, thereby preventing the development of disseminated intravascular coagulation, acute respiratory distress syndrome and multiple organ failure.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32987757</PMID>
<DateCompleted><Year>2020</Year>
<Month>10</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>10</Month>
<Day>29</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-3049</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>25</Volume>
<Issue>19</Issue>
<PubDate><Year>2020</Year>
<Month>Sep</Month>
<Day>24</Day>
</PubDate>
</JournalIssue>
<Title>Molecules (Basel, Switzerland)</Title>
<ISOAbbreviation>Molecules</ISOAbbreviation>
</Journal>
<ArticleTitle>Peptides: Prospects for Use in the Treatment of COVID-19.</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">E4389</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules25194389</ELocationID>
<Abstract><AbstractText>There is a vast practice of using antimalarial drugs, RAS inhibitors, serine protease inhibitors, inhibitors of the RNA-dependent RNA polymerase of the virus and immunosuppressants for the treatment of the severe form of COVID-19, which often occurs in patients with chronic diseases and older persons. Currently, the clinical efficacy of these drugs for COVID-19 has not been proven yet. Side effects of antimalarial drugs can worsen the condition of patients and increase the likelihood of death. Peptides, given their physiological mechanism of action, have virtually no side effects. Many of them are geroprotectors and can be used in patients with chronic diseases. Peptides may be able to prevent the development of the pathological process during COVID-19 by inhibiting SARS-CoV-2 virus proteins, thereby having immuno- and bronchoprotective effects on lung cells, and normalizing the state of the hemostasis system. Immunomodulators (RKDVY, EW, KE, AEDG), possessing a physiological mechanism of action at low concentrations, appear to be the most promising group among the peptides. They normalize the cytokines' synthesis and have an anti-inflammatory effect, thereby preventing the development of disseminated intravascular coagulation, acute respiratory distress syndrome and multiple organ failure.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khavinson</LastName>
<ForeName>Vladimir</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>Department of Biogerontology, Saint Petersburg Institute of Bioregulation and Gerontology, 197110 Saint Petersburg, Russia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>The Group of Peptide Regulation of Aging, Pavlov Institute of Physiology of RAS, 199034 St. Petersburg, Russia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Linkova</LastName>
<ForeName>Natalia</ForeName>
<Initials>N</Initials>
<Identifier Source="ORCID">0000-0001-5156-5421</Identifier>
<AffiliationInfo><Affiliation>Department of Biogerontology, Saint Petersburg Institute of Bioregulation and Gerontology, 197110 Saint Petersburg, Russia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Therapy, Geriatry, and Anti-Aging Medicine, Academy of Postgraduate Education under FSBU FSCC of FMBA of Russia, 125310 Moscow, Russia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Medical and Biological Disciplines, Belgorod State University, 308015 Belgorod, Russia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dyatlova</LastName>
<ForeName>Anastasiia</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Biogerontology, Saint Petersburg Institute of Bioregulation and Gerontology, 197110 Saint Petersburg, Russia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kuznik</LastName>
<ForeName>Boris</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Department of the normal physiology, Chita State Medical Academy, 672000 Chita, Russia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Umnov</LastName>
<ForeName>Roman</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Department of Biogerontology, Saint Petersburg Institute of Bioregulation and Gerontology, 197110 Saint Petersburg, Russia.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>09</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Switzerland</Country>
<MedlineTA>Molecules</MedlineTA>
<NlmUniqueID>100964009</NlmUniqueID>
<ISSNLinking>1420-3049</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019141">Respiratory System Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000254" MajorTopicYN="N">growth & development</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004211" MajorTopicYN="N">Disseminated Intravascular Coagulation</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
<QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012131" MajorTopicYN="N">Respiratory Insufficiency</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019141" MajorTopicYN="N">Respiratory System Agents</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">drugs</Keyword>
<Keyword MajorTopicYN="N">hemostasis</Keyword>
<Keyword MajorTopicYN="N">immunity</Keyword>
<Keyword MajorTopicYN="N">immunomodulators</Keyword>
<Keyword MajorTopicYN="N">peptides</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>08</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>09</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>09</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>9</Month>
<Day>29</Day>
<Hour>1</Hour>
<Minute>2</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>9</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>10</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32987757</ArticleId>
<ArticleId IdType="pii">molecules25194389</ArticleId>
<ArticleId IdType="doi">10.3390/molecules25194389</ArticleId>
<ArticleId IdType="pmc">PMC7583759</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2006 Sep;3(9):e343</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16968120</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Gerontol. 2011;24(2):278-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21957588</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lung. 2014 Oct;192(5):781-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25015171</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):507-513</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32007143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2008 Sep;82(17):8887-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18562523</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Dec;79(24):15511-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16306622</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hong Kong Med J. 2003 Dec;9(6):399-406</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14660806</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):514-523</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986261</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Mar;579(7798):270-273</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32015507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med (N Y). 2020 Jun 5;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32838355</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Mar 13;367(6483):1260-1263</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32075877</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Jul 2;319(3):746-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15184046</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bull Exp Biol Med. 2012 Jun;153(2):255-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22816096</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Ther. 2010 Oct;128(1):119-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20599443</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Metab Syndr. 2020 Jul - Aug;14(4):283-287</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32283499</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circ Res. 2020 May 8;126(10):1456-1474</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32264791</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2001 Feb 2;291(5505):884-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11229405</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105954</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32234467</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chest. 2002 Nov;122(5):1543-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12426251</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Metab Syndr. 2020 Jul - Aug;14(4):349-350</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32311651</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microb Pathog. 2020 Aug;145:104236</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32376359</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Microbes Infect. 2020 Dec;9(1):221-236</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31987001</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Sci (Lond). 2020 Mar 13;134(5):543-545</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32167153</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>AIMS Microbiol. 2020 Sep 24;6(3):350-360</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33029570</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32391667</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol Sin. 2020 Jun;35(3):266-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32125642</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhongguo Zhong Xi Yi Jie He Za Zhi. 2003 Sep;23(9):654-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14571610</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biogerontology. 2000;1(1):55-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11707921</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Mar 17;323(11):1061-1069</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32031570</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BioDrugs. 2018 Dec;32(6):531-546</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30488231</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Thromb Haemost. 2020 Apr;18(4):844-847</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32073213</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhonghua Xue Ye Xue Za Zhi. 2020 Mar 28;41(0):E006</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32220276</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Res. 1998;17(3):345-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9638477</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Res. 2020 Jul;157:104833</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32302706</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bull Exp Biol Med. 2012 Mar;152(5):615-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22803148</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biogerontology. 2010 Apr;11(2):139-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19830585</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Jun;78(12):6134-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15163706</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO J. 2005 Apr 20;24(8):1634-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15791205</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2014 Dec 15;74(24):7573-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25368020</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bull Exp Biol Med. 2003 Jun;135(6):590-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12937682</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EXCLI J. 2020 Mar 18;19:410-417</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32210742</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2020 Jun;80(6):656-665</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32283155</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Life Sci. 2020 Jun 1;250:117583</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32217117</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Korean Med Sci. 2020 Feb 17;35(6):e79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32056407</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2011 May;85(9):4122-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21325420</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16081529</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microbiol Immunol. 2000;44(3):205-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10789510</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2000 Nov;74(21):10194-201</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11024148</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ther Adv Musculoskelet Dis. 2018 Oct 07;10(10):195-199</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30327685</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomol Struct Dyn. 2020 Sep 10;:1-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32909528</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Turk J Biol. 2020 Jun 21;44(3):215-227</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32595358</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pathol. 2004 Jun;203(2):631-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15141377</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Gerontol. 2013;26(1):38-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24003727</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2003 Oct 10;310(1):78-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14511651</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Regul Homeost Agents. 1991 Apr-Jun;5(2):71-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1832810</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 1998 Nov;4(11):1302-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9809555</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Exp Pediatr. 2020 Apr;63(4):119-124</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32252141</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Mal Infect. 2020 Jun;50(4):384</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32240719</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bull Exp Biol Med. 2003 Jun;135(6):600-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12937685</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Jun;92(6):556-563</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32104907</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Gerontol. 2013;26(1):20-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24003726</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2011 Jan;85(2):873-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21068237</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Gerontol. 2002;10:74-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12577695</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2006 Feb 10;281(6):3198-203</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16339146</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Biomed. 2020 Mar 19;91(1):157-160</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32191675</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2019 Mar;17(3):181-192</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30531947</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mech Ageing Dev. 2001 Jan;122(1):41-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11163623</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2020 May;26(5):672-675</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32296168</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Des Deliv. 1990 Sep;6(3):213-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2076180</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Gerontol. 2012;25(4):696-708</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23734519</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci China Life Sci. 2020 Mar;63(3):457-460</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32009228</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Stem Cell Rev Rep. 2020 Feb;16(1):118-125</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31808038</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bull Exp Biol Med. 2009 Jul;148(1):94-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19902107</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 2012 Aug;167(2):322-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22659295</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci China Life Sci. 2020 Mar;63(3):364-374</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32048163</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1979 Jun 22;204(4399):1309-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">451537</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 28;323(16):1610-1612</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32129805</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int Rev Immunol. 2020;39(4):153-162</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32347747</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Cardiol. 2020 Jul 1;5(7):745-747</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32242890</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Biochem. 2000;69:531-69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10966468</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2020 Mar 27;11(1):1620</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32221306</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Regul Pept. 1984 Oct;9(3):155-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6098937</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Regul Integr Comp Physiol. 2008 Dec;295(6):R1953-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18945956</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2020 Feb 17;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32081428</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Thromb Haemost. 2020 May;18(5):1094-1099</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32220112</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hypertens. 2012 Feb;30(2):375-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22179088</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biomed Res Int. 2020 May 11;2020:2683286</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32461973</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2019 Nov 18;47(20):10553-10563</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31598715</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2018 Aug 13;14(8):e1007236</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30102747</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Placenta. 2006 Feb-Mar;27(2-3):200-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16338465</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bull Exp Biol Med. 2019 Nov;168(1):141-144</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31761987</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2010 May 18;17(5):443-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20478527</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Khirurgiia (Mosk). 2012;(11):19-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23258355</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Pharm Des. 2006;12(35):4573-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17168763</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2020 Apr 16;181(2):271-280.e8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32142651</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rev Med Virol. 2020 May;30(3):e2109</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32314850</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Biochem. 2001;70:777-810</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11395423</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Respir Res. 2018 Aug 2;19(1):145</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30068332</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2020 May;8(5):475-481</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32105632</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2003 Aug;77(16):8801-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12885899</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Russie</li>
</country>
<region><li>District fédéral central</li>
</region>
<settlement><li>Moscou</li>
</settlement>
</list>
<tree><country name="Russie"><noRegion><name sortKey="Khavinson, Vladimir" sort="Khavinson, Vladimir" uniqKey="Khavinson V" first="Vladimir" last="Khavinson">Vladimir Khavinson</name>
</noRegion>
<name sortKey="Dyatlova, Anastasiia" sort="Dyatlova, Anastasiia" uniqKey="Dyatlova A" first="Anastasiia" last="Dyatlova">Anastasiia Dyatlova</name>
<name sortKey="Khavinson, Vladimir" sort="Khavinson, Vladimir" uniqKey="Khavinson V" first="Vladimir" last="Khavinson">Vladimir Khavinson</name>
<name sortKey="Kuznik, Boris" sort="Kuznik, Boris" uniqKey="Kuznik B" first="Boris" last="Kuznik">Boris Kuznik</name>
<name sortKey="Linkova, Natalia" sort="Linkova, Natalia" uniqKey="Linkova N" first="Natalia" last="Linkova">Natalia Linkova</name>
<name sortKey="Linkova, Natalia" sort="Linkova, Natalia" uniqKey="Linkova N" first="Natalia" last="Linkova">Natalia Linkova</name>
<name sortKey="Linkova, Natalia" sort="Linkova, Natalia" uniqKey="Linkova N" first="Natalia" last="Linkova">Natalia Linkova</name>
<name sortKey="Umnov, Roman" sort="Umnov, Roman" uniqKey="Umnov R" first="Roman" last="Umnov">Roman Umnov</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/BiopestPeptidV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000051 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000051 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    BiopestPeptidV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32987757
   |texte=   Peptides: Prospects for Use in the Treatment of COVID-19.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32987757" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a BiopestPeptidV1

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 19:22:35 2020. Site generation: Thu Nov 19 19:33:26 2020

	Serveur d'exploration sur les peptides biopesticides
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les peptides biopesticides

Peptides: Prospects for Use in the Treatment of COVID-19.

Peptides: Prospects for Use in the Treatment of COVID-19.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki